CR9723A - Nueva forma cristalina de un derivado de piridazino[4,5-b] indol - Google Patents

Nueva forma cristalina de un derivado de piridazino[4,5-b] indol

Info

Publication number
CR9723A
CR9723A CR9723A CR9723A CR9723A CR 9723 A CR9723 A CR 9723A CR 9723 A CR9723 A CR 9723A CR 9723 A CR9723 A CR 9723A CR 9723 A CR9723 A CR 9723A
Authority
CR
Costa Rica
Prior art keywords
piridazino
indol
derivative
crystal form
new crystal
Prior art date
Application number
CR9723A
Other languages
English (en)
Inventor
L Rocco William
D Higgins John
Original Assignee
Sanofi Aventis Us Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37546937&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR9723(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Us Llc filed Critical Sanofi Aventis Us Llc
Publication of CR9723A publication Critical patent/CR9723A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se describe una nueva forma cristalina de 7-cloro-N,N,5-trimetil-4-oxo-3-fenil-3,5-dihidro-4H-piridazino[4,5-b]indol-1-acetamida, procesos para preparar dicha forma cristalina de 7-cloro-N,N,5-trimetil-4-oxo-3-fenil-3,5-dihidro-4H-piridazino[4,5-b]indol-1-acetamida, composiciones que comprenden dicha forma mazclada con uno o mas excipientes farmaceuticamente aceptables, y usos para la misma.
CR9723A 2005-08-29 2008-02-11 Nueva forma cristalina de un derivado de piridazino[4,5-b] indol CR9723A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71215305P 2005-08-29 2005-08-29

Publications (1)

Publication Number Publication Date
CR9723A true CR9723A (es) 2008-06-18

Family

ID=37546937

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9723A CR9723A (es) 2005-08-29 2008-02-11 Nueva forma cristalina de un derivado de piridazino[4,5-b] indol

Country Status (32)

Country Link
US (1) US7683062B2 (es)
EP (1) EP1924585B1 (es)
JP (1) JP5063600B2 (es)
KR (2) KR20080050577A (es)
CN (1) CN101253176B (es)
AR (1) AR057099A1 (es)
AT (1) ATE531717T1 (es)
AU (1) AU2006285142B2 (es)
BR (1) BRPI0615259A2 (es)
CA (1) CA2619284C (es)
CR (1) CR9723A (es)
CY (1) CY1112317T1 (es)
DK (1) DK1924585T3 (es)
EA (1) EA014164B1 (es)
EC (1) ECSP088209A (es)
ES (1) ES2375841T3 (es)
HK (1) HK1123794A1 (es)
HR (1) HRP20120073T1 (es)
IL (1) IL189276A (es)
MA (1) MA30000B1 (es)
NO (1) NO20081365L (es)
NZ (1) NZ566087A (es)
PL (1) PL1924585T3 (es)
PT (1) PT1924585E (es)
RS (1) RS52318B (es)
SI (1) SI1924585T1 (es)
TN (1) TNSN08059A1 (es)
TW (1) TW200813060A (es)
UA (1) UA91716C2 (es)
UY (1) UY29771A1 (es)
WO (1) WO2007027525A1 (es)
ZA (1) ZA200801890B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2678124C (en) * 2003-11-17 2014-10-07 Merck Eprova Ag Crystalline forms of (6r)-l-erythro-tetrahydrobiopterin dihydrochloride
WO2005118586A1 (en) * 2004-06-02 2005-12-15 Sandoz Ag Meropenem intermediate in crystalline form
US8188138B2 (en) * 2005-09-21 2012-05-29 4Sc Ag Sulphonylpyrrole hydrochloride salts as histone deacetylases inhibitors
BRPI0617947A2 (pt) * 2005-10-31 2011-08-09 Janssen Pharmaceutica Nv processos para a preparação de derivados de piperazinil e diazapanil benzamida
CA2656057C (en) * 2006-06-16 2012-10-02 H. Lundbeck A/S Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl]piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
CN101568544B (zh) * 2006-10-27 2016-10-26 西格诺药品有限公司 包含4‑[9‑(四氢‑呋喃‑3‑基)‑8‑(2,4,6‑三氟‑苯氨基)‑9h‑嘌呤‑2‑基氨基]‑环己烷‑1‑醇的固体形式，其组合物，及其用途
EP2085397A1 (en) * 2008-01-21 2009-08-05 Esteve Quimica, S.A. Crystalline form of abacavir
US7935817B2 (en) * 2008-03-31 2011-05-03 Apotex Pharmachem Inc. Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof
AR071318A1 (es) * 2008-04-15 2010-06-09 Basilea Pharmaceutica Ag Benzhidril ester del acido (6r,7r)-7-{2-(5-amino-[1,2,4]tiadiazol-3-il)-2-[(z)-tritiloxiimino]-acetilamino}-3-[(r)-1'-terc-butoxicarbonil-2-oxo-[1,3']bipirrolidinil-(3e)-ilidenometil]-8-oxo-5-tia-1-aza-biciclo[4.2.0]oct-2-eno-2-carboxilico cristalino; su elaboracion y uso
US8097719B2 (en) * 2008-07-15 2012-01-17 Genesen Labs Meropenem intermediate in novel crystalline form and a method of manufacture of meropenem
AU2009283039A1 (en) * 2008-08-18 2010-02-25 Sanofi-Aventis U.S. Llc Process for preparing polymorph of 7-chloro-N, N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydr0-4H-pyridazin0[4,5-b]indole-1-acetamide
PT2544679T (pt) 2010-03-12 2019-07-11 Omeros Corp Inibidores de pde-10 e composições e métodos relacionados
CN103189360A (zh) * 2010-09-01 2013-07-03 艾尼纳制药公司 5-ht2c激动剂的非吸湿性盐
CN103930419B (zh) * 2011-09-30 2016-06-01 广东东阳光药业有限公司 阿齐沙坦的晶型及其制备方法
NZ716462A (en) 2014-04-28 2017-11-24 Omeros Corp Optically active pde10 inhibitor
NZ716494A (en) 2014-04-28 2017-07-28 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
US9879002B2 (en) 2015-04-24 2018-01-30 Omeros Corporation PDE10 inhibitors and related compositions and methods
JP2018535969A (ja) 2015-11-04 2018-12-06 オメロス コーポレーション Ｐｄｅ１０阻害剤の固体状態形態
CN111303230B (zh) * 2020-03-09 2021-07-13 中国食品药品检定研究院 一种黄体酮共晶物及其制备方法和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2766823B1 (fr) * 1997-07-30 1999-10-08 Synthelabo Derives de 4-oxo-3,5-dihydro-4h-pyridazino[4,5-b] indole-1-acetamide, leur preparation et leur application en therapeutique
FR2788696B1 (fr) 1999-01-26 2004-03-05 Synthelabo Utilisation de derives de pyridazino [4,5-b] indole-1-acetamide pour la preparation de medicaments destines aux maladies du systeme nerveux central
FR2829939B3 (fr) 2001-09-21 2003-11-28 Sanofi Synthelabo Utilisation du 7-chloro-n,n,5-trimethyl-4-oxo-3-phenyl-3,5- dihydro-4h-pyridazino(4,5-b)indole-1-acetamide pour la preparation de medicaments destines au traitement de la polyarthrite rhumatoide
US20050220881A1 (en) 2003-10-10 2005-10-06 Bvm Holding Co. Pharmaceutical composition

Also Published As

Publication number Publication date
IL189276A (en) 2012-07-31
TW200813060A (en) 2008-03-16
US20080139569A1 (en) 2008-06-12
AU2006285142A1 (en) 2007-03-08
EA200800716A1 (ru) 2008-08-29
PL1924585T3 (pl) 2012-08-31
EA014164B1 (ru) 2010-10-29
IL189276A0 (en) 2008-08-07
DK1924585T3 (da) 2012-02-27
TNSN08059A1 (en) 2009-07-14
RS52318B (en) 2012-12-31
ZA200801890B (en) 2009-11-25
ECSP088209A (es) 2008-06-30
HRP20120073T1 (hr) 2012-07-31
MA30000B1 (fr) 2008-12-01
UY29771A1 (es) 2007-03-30
BRPI0615259A2 (pt) 2011-05-17
UA91716C2 (ru) 2010-08-25
HK1123794A1 (en) 2009-06-26
PT1924585E (pt) 2012-01-19
EP1924585A1 (en) 2008-05-28
WO2007027525A1 (en) 2007-03-08
ATE531717T1 (de) 2011-11-15
NO20081365L (no) 2008-04-03
KR20080050577A (ko) 2008-06-09
ES2375841T3 (es) 2012-03-06
CA2619284C (en) 2014-04-29
CN101253176B (zh) 2012-04-18
JP2009506116A (ja) 2009-02-12
EP1924585B1 (en) 2011-11-02
AR057099A1 (es) 2007-11-14
JP5063600B2 (ja) 2012-10-31
US7683062B2 (en) 2010-03-23
SI1924585T1 (sl) 2012-09-28
CN101253176A (zh) 2008-08-27
AU2006285142B2 (en) 2012-06-14
CA2619284A1 (en) 2007-03-08
CY1112317T1 (el) 2015-12-09
KR20130087059A (ko) 2013-08-05
NZ566087A (en) 2011-03-31

Similar Documents

Publication Publication Date Title
CR9723A (es) Nueva forma cristalina de un derivado de piridazino[4,5-b] indol
UY29459A1 (es) Forma cristalina ortorrómbica del maleato de asenapina y su uso en el tratamiento de trastornos mentales
CL2006001266A1 (es) Formas solidas cristalinas i, ii, iii, iv y v de tigeciclina; procedimiento de preparacion de las formas cristalinas ii, iv y v; composicion farmaceutica que comprende las formas cristalinas; y su uso para tratar infecciones bacterianas.
CL2008002538A1 (es) Compuestos derivados de indol sustituidos; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion viral
CL2010001348A1 (es) Compuestos derivados de 1-oxo-2,3-dihidro-1h-isoindolin-5-il)-isoxazol-3-carboxamida, potenciadores de los mglur2; composicion farmaceutica; y su uso para aliviar los sintomas o disminuir la aparicion de los sintomas de ezquizofrenia o ansiedad.
AR047928A1 (es) Derivados de tetrahidropiridoindol
CL2008002539A1 (es) Compuestos derivados de indol sustituidos; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion viral
NO20091395L (no) Nye tiofenderivater
NO20076447L (no) Bicykliske derivater som modulatorer av ionekanaler
NO20083630L (no) Nye pyridinderivater
CL2007003686A1 (es) Compuestos derivados de indol con anillo unido en las posiciones 4,5; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para tratar una infeccion viral.
NO20074431L (no) Pyrrolopyrimidiner nyttige som proteinkinaseinhibitorer
UY29099A1 (es) Fenilaminotiazoles sustituidos y su uso
AR058904A1 (es) Proceso mejorado para la preparacion de un derivado de 5h-pirrolo[3,4-b] pirazina opticamente activo
ECSP12011935A (es) Triazolopiridinas
AR054347A1 (es) Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
CL2008002540A1 (es) Compuestos derivados aza-indol-2,3-sustituidos; composicion farmaceutica; y uso ene l tratamiento de una infeccion viral.
NO20076648L (no) Novel thiophene derivatives
ECSP077316A (es) Compuestos imidazo-3-il-amina bicíclicos sustituidos
ECSP10010129A (es) Inhibidores de quinasas símil polo
GT200600369A (es) Proceso
ECSP077306A (es) Derivados de alquiliden-tetrahidronaftaleno, procedimiento para su preparación y su uso como antiinflamatorios
CL2007002919A1 (es) Compuestos derivados de pirido[2,3-b]indol, inhibidores de quinasa; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar cancer, entre otras enfermedades.
CR11584A (es) Derivados de oxindol sustituidos y uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina
DK2185561T3 (da) Derivater af 1,2,3,4-tetrahydropyrrolo(1,2-a)pyrazin-6-carboxamid og 2,3,4,5-tetrahydroprrolo(1,2-a)-diazepin-7-carboxamid, fremstilling deraf og terapeutisk anvendelse deraf